skip to main content

Dupilumab for Eczema — RACP Paediatrics MCQ

Instant feedback + full explanation. One question, done properly.

ModerateDermatologyDupilumab for EczemaRACP Paediatrics

A 10-year-old has severe atopic dermatitis uncontrolled despite optimised topical therapy (emollients, topical corticosteroids, calcineurin inhibitors). What systemic therapy has recently been approved for moderate-severe atopic dermatitis in children ≥6 years?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: A — Dupilumab (anti-IL-4/IL-13 monoclonal antibody)

Dupilumab (anti-IL-4Rα monoclonal antibody) is approved for moderate-severe atopic dermatitis in children ≥6 years uncontrolled with topical therapy. It significantly improves disease severity and quality of life with a favourable safety profile (main side effect is conjunctivitis). It is a subcutaneous injection given every 2-4 weeks.

Reference: Therapeutic Guidelines – 2024 – Dermatology: Atopic Dermatitis